Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

NTHIBullishIndustry Newsnews

Medium materiality6/10

NeOnc's NEO100 posts strong Phase 2a signal; FDA path ahead for NTHI

Sep 22, 2026, 3:35 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive early efficacy signals and a defined FDA path could drive modest upside in NTHI, though small sample size and promotional nature temper conviction.

AI summary

What happened, with direct paths to the underlying reporting

NeOnc’s NEO100 intranasal delivery showed a meaningful Phase 2a signal in IDH1-mutant glioma, with six-month progression-free survival at 48.9% and median overall survival of 26.09 months, and limited toxicity. The company plans a Type B FDA meeting to discuss a potential registrational pathway, a potential inflection point if larger trials replicate the signal. The result highlights nose-to-brain delivery as a broader concept, though replication risk remains high in a small, biomarker-defined cohort.

NEO100 intranasal therapy targets IDH1-mutant glioma; Phase 2a shows strong signals. Six-month PFS 48.9%; p=0.0047.
OS median 26.09 months; five of 24 patients remained on treatment.
No major toxicities; adverse events predominantly low-grade.
FDA Type B meeting planned to discuss registrational pathway.
Novocure TTFields competitor; TRIDENT trial failed to meet OS.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.